Combined injection of intralesional steroids with BTX-A appears to be superior to either therapy alone and offer the best benefit of safer and more efficacious response with lesser side effects.

Comparison of intralesional triamcinolone acetonide, botulinum toxin type A, and their combination for the treatment of keloid lesions
Hend D. Gamil, Fathia M. Khattab ORCID Icon, Mohammed M. El fawa & Safaa E. Eldeeb
Received 10 Apr 2019, Accepted 26 May 2019, Accepted author version posted online: 11 Jun 2019, Published online: 05 Jul 2019
Download citation  https://doi.org/10.1080/09546634.2019.1628171 

Select Language​▼
Translator disclaimer
Abstract
Objective: Despite the myriad options available, there is no universally the accepted treatment for keloids. Our objective was to compare three regiments and establish superiority in terms of objective and subjective outcomes.

Approach: In this intervention study, 50 patients were enrolled. The Group I: included 26 patients with at least two keloid lesions subjected to intralesional triamcinolone acetonide in left-sided lesions and intralesional botulinum toxin type A in right-sided lesions. While group II included 24 patients subjected to a combination of both intralesional TAC and BTX-A. Injections were done for a total of three sessions 4 weeks apart. Color Doppler ultrasound (CDU) was done before and one month after treatment.

Results: In terms of thickness and surface area the keloids responded significantly better to combined TCA and BTX versus TCA alone or BTX alone (p .0001). Also improvement in transverse and longitudinal axis was significantly higher in combined therapy (p < .0001 and .004, respectively).

Conclusion: Combined injection of intralesional steroids with BTX-A appears to be superior to either therapy alone and offer the best benefit of safer and more efficacious response with lesser side effects.

Keywords: Keloid, intralesional, triamcinolone, Botulinum toxin type A (BTX-A)